FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310363049> ?p ?o ?g. }

• W4310363049 abstract "Abstract Background Vaso–occlusive crises (VOCs) are acute and common painful complication of sickle cell disease (SCD), and are the main reason behind the frequent emergency department visits among SCD patients. Hydroxyurea (HU) is an old and commonly used medication that demonstrated its effectiveness in reducing the risk of VOCs and the incidence of hospitalization. Although multiple studies have examined the impact of HU on the rates of VOCs, few have explored its effectiveness among SCD patients in Saudi Arabia. Methods This was a single–center retrospective cohort study in which the electronic medical records of patients with SCD who have not had any previous exposure to HU prior to the initiation of HU treatment for ≥12 months were recruited. Paired t–test was conducted to examine the difference in the rates of VOCs, and levels of hemoglobin (Hgb), hematocrit (HCT), and platelet counts (PLT Ct) prior to the initiation of HU therapy and 12 months later. Multiple linear regression was conducted to examine whether age, gender, use of opioid analgesics, Hgb, HCT, and PLT Ct levels predict higher or lower rates of VOCs. Results One hundred and fifty–six patients met the inclusion criteria and were included in the analysis. About 51% of the patients were males, and their mean age was 12.69 years. The mean HU dosage was 16.52 mg/kg/day, and the mean reduction in the rate of VOCs was 1.36 events per patient per year (95% CI [1.03–1.70], p < 0.0001) after the initiation of HU. Females were more likely to have greater reduction in the rates of VOCs in comparison to their male counterparts (β–estimate = 12.85, 95% CI [0.759–24.93], p = 0.0374). Conclusion The use of HU results in a significant reduction in the rates of VOCs and emergency department visits. Future studies with robust research designs should be conducted to further examine the impact of HU on VOCs, hospitalization, and length of stay as well as compare HU to other newly approved medications for SCD, such as crizanlizumab." @default.
• W4310363049 created "2022-12-09" @default.
• W4310363049 creator A5009714568 @default.
• W4310363049 creator A5011589146 @default.
• W4310363049 creator A5018571761 @default.
• W4310363049 creator A5030947217 @default.
• W4310363049 creator A5045881050 @default.
• W4310363049 creator A5058607514 @default.
• W4310363049 creator A5077166830 @default.
• W4310363049 creator A5084162786 @default.
• W4310363049 creator A5085826026 @default.
• W4310363049 creator A5089062568 @default.
• W4310363049 date "2022-11-29" @default.
• W4310363049 modified "2023-09-27" @default.
• W4310363049 title "The impact of Hydroxyurea on the rates of Vaso–occlusive crises in patients with sickle cell disease in Saudi Arabia: a single–center study" @default.
• W4310363049 cites W1553559411 @default.
• W4310363049 cites W1582692942 @default.
• W4310363049 cites W2025536685 @default.
• W4310363049 cites W2027662398 @default.
• W4310363049 cites W2042283631 @default.
• W4310363049 cites W2053495832 @default.
• W4310363049 cites W2065773232 @default.
• W4310363049 cites W2069988928 @default.
• W4310363049 cites W2104724413 @default.
• W4310363049 cites W2149093067 @default.
• W4310363049 cites W2179309174 @default.
• W4310363049 cites W2210742289 @default.
• W4310363049 cites W2320032845 @default.
• W4310363049 cites W2322018156 @default.
• W4310363049 cites W2588514944 @default.
• W4310363049 cites W2607346125 @default.
• W4310363049 cites W2783276969 @default.
• W4310363049 cites W2898014977 @default.
• W4310363049 cites W2929814883 @default.
• W4310363049 cites W2994366664 @default.
• W4310363049 cites W2998771677 @default.
• W4310363049 cites W3000542862 @default.
• W4310363049 cites W3016435988 @default.
• W4310363049 cites W3035330065 @default.
• W4310363049 cites W3132665799 @default.
• W4310363049 cites W3133170511 @default.
• W4310363049 cites W3210300267 @default.
• W4310363049 cites W4200548974 @default.
• W4310363049 cites W4211242268 @default.
• W4310363049 cites W4255770260 @default.
• W4310363049 cites W59714281 @default.
• W4310363049 doi "https://doi.org/10.1186/s12873-022-00751-0" @default.
• W4310363049 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36447134" @default.
• W4310363049 hasPublicationYear "2022" @default.
• W4310363049 type Work @default.
• W4310363049 citedByCount "0" @default.
• W4310363049 crossrefType "journal-article" @default.
• W4310363049 hasAuthorship W4310363049A5009714568 @default.
• W4310363049 hasAuthorship W4310363049A5011589146 @default.
• W4310363049 hasAuthorship W4310363049A5018571761 @default.
• W4310363049 hasAuthorship W4310363049A5030947217 @default.
• W4310363049 hasAuthorship W4310363049A5045881050 @default.
• W4310363049 hasAuthorship W4310363049A5058607514 @default.
• W4310363049 hasAuthorship W4310363049A5077166830 @default.
• W4310363049 hasAuthorship W4310363049A5084162786 @default.
• W4310363049 hasAuthorship W4310363049A5085826026 @default.
• W4310363049 hasAuthorship W4310363049A5089062568 @default.
• W4310363049 hasBestOaLocation W43103630491 @default.
• W4310363049 hasConcept C118552586 @default.
• W4310363049 hasConcept C120665830 @default.
• W4310363049 hasConcept C121332964 @default.
• W4310363049 hasConcept C126322002 @default.
• W4310363049 hasConcept C167135981 @default.
• W4310363049 hasConcept C187212893 @default.
• W4310363049 hasConcept C2778620579 @default.
• W4310363049 hasConcept C2778917026 @default.
• W4310363049 hasConcept C2779134260 @default.
• W4310363049 hasConcept C2780073493 @default.
• W4310363049 hasConcept C2780441568 @default.
• W4310363049 hasConcept C2780724011 @default.
• W4310363049 hasConcept C2780959883 @default.
• W4310363049 hasConcept C2780976302 @default.
• W4310363049 hasConcept C61511704 @default.
• W4310363049 hasConcept C71924100 @default.
• W4310363049 hasConcept C72563966 @default.
• W4310363049 hasConceptScore W4310363049C118552586 @default.
• W4310363049 hasConceptScore W4310363049C120665830 @default.
• W4310363049 hasConceptScore W4310363049C121332964 @default.
• W4310363049 hasConceptScore W4310363049C126322002 @default.
• W4310363049 hasConceptScore W4310363049C167135981 @default.
• W4310363049 hasConceptScore W4310363049C187212893 @default.
• W4310363049 hasConceptScore W4310363049C2778620579 @default.
• W4310363049 hasConceptScore W4310363049C2778917026 @default.
• W4310363049 hasConceptScore W4310363049C2779134260 @default.
• W4310363049 hasConceptScore W4310363049C2780073493 @default.
• W4310363049 hasConceptScore W4310363049C2780441568 @default.
• W4310363049 hasConceptScore W4310363049C2780724011 @default.
• W4310363049 hasConceptScore W4310363049C2780959883 @default.
• W4310363049 hasConceptScore W4310363049C2780976302 @default.
• W4310363049 hasConceptScore W4310363049C61511704 @default.
• W4310363049 hasConceptScore W4310363049C71924100 @default.
• W4310363049 hasConceptScore W4310363049C72563966 @default.
• W4310363049 hasIssue "1" @default.
• W4310363049 hasLocation W43103630491 @default.
• W4310363049 hasLocation W43103630492 @default.

• next